ATE247967T1 - Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen - Google Patents

Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen

Info

Publication number
ATE247967T1
ATE247967T1 AT99923960T AT99923960T ATE247967T1 AT E247967 T1 ATE247967 T1 AT E247967T1 AT 99923960 T AT99923960 T AT 99923960T AT 99923960 T AT99923960 T AT 99923960T AT E247967 T1 ATE247967 T1 AT E247967T1
Authority
AT
Austria
Prior art keywords
brotizolam
zopiclone
zolpidem
treatment
sleep disorders
Prior art date
Application number
AT99923960T
Other languages
English (en)
Inventor
Shigenori Ohkawa
Masaomi Miyamoto
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE247967T1 publication Critical patent/ATE247967T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99923960T 1998-06-09 1999-06-08 Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen ATE247967T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16027098 1998-06-09
PCT/JP1999/003057 WO1999063977A2 (en) 1998-06-09 1999-06-08 Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone, triazolam and brotizolam for treating or preventing sleep disorders

Publications (1)

Publication Number Publication Date
ATE247967T1 true ATE247967T1 (de) 2003-09-15

Family

ID=15711379

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99923960T ATE247967T1 (de) 1998-06-09 1999-06-08 Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen

Country Status (10)

Country Link
US (1) US6348485B1 (de)
EP (1) EP1100508B8 (de)
KR (1) KR100642024B1 (de)
CN (1) CN1206996C (de)
AR (1) AR019639A1 (de)
AT (1) ATE247967T1 (de)
AU (1) AU4060599A (de)
CA (1) CA2332521C (de)
DE (1) DE69910795T2 (de)
WO (1) WO1999063977A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2428817C (en) * 2000-11-17 2010-06-01 Takeda Chemical Industries, Ltd. Copolyvidone-containing preparation
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
AU2003285012A1 (en) * 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP3735668B2 (ja) * 2002-11-27 2006-01-18 独立行政法人情報通信研究機構 脳機能測定装置及び脳機能測定方法
AU2004237943A1 (en) * 2003-05-19 2004-11-25 Sciencom Ltd Further therapeutic use of zolpidem
CA2548917C (en) * 2003-12-11 2014-09-23 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
US20050164987A1 (en) * 2003-12-24 2005-07-28 Barberich Timothy J. Melatonin combination therapy for improving sleep quality
KR20130116378A (ko) * 2004-02-17 2013-10-23 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
US20050267176A1 (en) * 2004-02-18 2005-12-01 Sepracor Inc. Dopamine-agonist combination therapy for improving sleep quality
EP1750677B1 (de) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
TWI400220B (zh) * 2004-09-13 2013-07-01 Takeda Pharmaceutical 光活性胺衍生物的製法
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
GT200600042A (es) * 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
BRPI0607684A2 (pt) * 2005-04-04 2009-09-22 Takeda Pharmaceutical composição farmacêutica, método para prevenir ou tratar distúrbios de depressão ou ansiedade, e, uso de (s)-n-[2-(1,6,7,8-tetraidro-2h-indeno[5,4-b]furan-8-il)-eti l]-propionamida
WO2006128022A2 (en) * 2005-05-25 2006-11-30 Transcept Pharmaceuticals, Inc. Solid compositions and methods for treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
ES2366381T3 (es) * 2005-06-22 2011-10-19 Takeda Pharmaceutical Company Limited Comprimido que contiene un ingrediente activo difícilmente soluble.
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
EP3263117A1 (de) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
TW200803837A (en) * 2006-03-20 2008-01-16 Takeda Pharmaceutical Prophylactic or therapeutic agent for irritable bowel syndrome
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
EP2098519A1 (de) * 2007-05-31 2009-09-09 Teva Pharmaceutical Industries Ltd. Verfahren zur Synthese von Ramelteon und seinen Zwischenprodukten
WO2009060318A2 (en) * 2007-07-12 2009-05-14 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ramelteon and processes for preparation thereof
US20090082432A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched ramelteon
EP2344468A4 (de) * 2008-11-14 2012-08-01 Watson Pharma Private Ltd Verfahren zur herstellung von ramelteon
EP2370136A4 (de) * 2008-12-01 2015-12-30 Map Pharmaceuticals Inc Inhalative freisetzungsverfahren und vorrichtungen
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
EP2483258A1 (de) * 2009-09-29 2012-08-08 Lonza Ltd. Verfahren zur herstellung von 1,2,6,7-tetrahydro-8h-inden[5,4-b]furan-8-on
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2014100292A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987052A (en) 1969-03-17 1976-10-19 The Upjohn Company 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
OA04285A (fr) 1972-01-07 1979-12-31 Rhone Poulenc Sa Nouveaux dérivés de la pyrrolo (3,4-b) pyrazine et leur préparation.
AT338799B (de) 1974-03-02 1977-09-12 Boehringer Sohn Ingelheim Verfahren zur herstellung neuer substituierter 6-aryl-4h-s-triazolo-(3,4c)-thieno-(2,3e)-1,4-diazepine und ihrer salze
FR2600650B1 (fr) 1986-06-27 1988-09-09 Synthelabo Procede de preparation d'imidazopyridines et composes intermediaires
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
HU224220B1 (hu) * 1996-03-08 2005-06-28 Takeda Pharmaceutical Company Limited Triciklusos vegyületek, eljárás előállításukra és alkalmazásuk
GB9613969D0 (en) * 1996-07-03 1996-09-04 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
WO1999063977A3 (en) 2001-03-29
CA2332521A1 (en) 1999-12-16
WO1999063977A2 (en) 1999-12-16
EP1100508B1 (de) 2003-08-27
CN1206996C (zh) 2005-06-22
US6348485B1 (en) 2002-02-19
CA2332521C (en) 2009-02-10
AU4060599A (en) 1999-12-30
DE69910795T2 (de) 2004-06-17
EP1100508B8 (de) 2004-01-07
AR019639A1 (es) 2002-02-27
EP1100508A2 (de) 2001-05-23
DE69910795D1 (de) 2003-10-02
CN1309565A (zh) 2001-08-22
KR100642024B1 (ko) 2006-11-06
KR20010052676A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
ATE247967T1 (de) Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen
DE60023873D1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE69835103D1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
CY2013041I1 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
EE9700031A (et) Pürido-liitunud tienüül- ja furanüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
HUP0103856A2 (hu) Gyógyszerkészítmény akut rendellenességek kezelésére
DE50010833D1 (de) Pharmazeutisches präparat enthaltend diamorphin und vitamin e seine verwendung zur behandlung der opiatsucht
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
NO963731D0 (no) Behandling av fedme-kompulsive sykdommer med 5HT2-antagonister
ATE318604T1 (de) Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DE60121047D1 (de) Pharmazeutische zusammensetzung zur behandlung von phimose mit einem topischen corticosteroid
DE10081194D2 (de) Darreichungsform zur Applikation in Körperöffnungen
DE69809284D1 (de) Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
DE69738320D1 (de) Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch
PL362566A1 (en) Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties